Novo Nordisk pivots from rare diseases to obesity, scrapping a Danish plant and 400 jobs, as it races to defend its GLP-1 dominance against Eli Lilly and generic competition.<\/p>\n
Novo Nordisk is undergoing a sweeping strategic recalibration, abandoning a planned manufacturing site for rare-disease drugs in Odense, Denmark, while doubling down on its metabolic core. The moves come as the Danish pharma giant faces intensifying competition from Eli Lilly and generic challengers\u2014and pins its hopes on a new generation of weight-loss therapies.<\/p>\n
The Odense facility, originally designed to produce medicines for rare diseases, will now serve only as a warehouse. The shift eliminates 400 planned permanent jobs and leaves more than 150 construction workers out of work immediately. Management cited \u201csignificant shifts in global demand\u201d for the abrupt change. The decision underscores the pressure on Novo Nordisk\u2019s legacy rare-disease portfolio as it redirects resources toward the far larger obesity and diabetes market.<\/p>\n
That market is vast but increasingly contested. Worldwide, over 900 million people live with obesity, yet only about 1% currently receive branded drugs. Novo Nordisk commands roughly 55% of weekly injectable GLP-1 prescriptions in the U.S., where its oral Wegovy pill\u2014launched early this year\u2014has already reached more than one million patients. The company says Wegovy now accounts for 65% of all new obesity therapy prescriptions in the U.S., a notable comeback after Eli Lilly had seized momentum.<\/p>\n
However, the threat from cheaper alternatives is growing. In India, Dr. Reddy\u2019s Laboratories recently secured approval for a generic version of oral semaglutide, the active ingredient in Novo Nordisk\u2019s oral formulation. Although the core patent for oral semaglutide runs until 2031, the regulatory green light in a major market signals long-term pricing risk. Novo Nordisk has already responded with price cuts to defend its position.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n While the patent clock ticks, the pipeline is the focus. Novo Nordisk\u2019s lead experimental candidate, CagriSema\u2014a combination of a GLP-1 receptor agonist and an amylin analogue\u2014has been submitted for U.S. approval. A decision is expected in the fourth quarter of 2026. In the REDEFINE 1 trial, CagriSema delivered a 22.7% mean weight loss after 68 weeks, compared with 16.1% for semaglutide alone. But early data fell short of Eli Lilly\u2019s Zepbound, and the final comparison will determine commercial reception. A large cardiovascular outcomes study, REDEFINE 3, is ongoing with 7,000 participants.<\/p>\n Elsewhere in the pipeline, Novo Nordisk is developing multi-hormone candidates such as Amycretin and UBT251. In the first quarter, it logged six regulatory approvals and more than ten new study starts. The company also divested its Parkinson\u2019s cell-therapy candidate, STEM-PD, to Cellular Intelligence, a Meta-backed AI startup, in exchange for an equity stake, milestone payments, and royalties. The therapy already holds FDA Fast Track status.<\/p>\n On the financial front, the quarterly update in May showed adjusted revenue of 70.1 billion Danish kroner, down 10% year-on-year, and adjusted earnings per share falling 3%. The company narrowed its 2026 outlook to a currency-adjusted revenue and operating profit decline of 4% to 12%, less severe than previously feared. R&D and marketing spending in the first quarter totaled 22.4 billion kroner, while a share buyback program of up to 15 billion kroner is underway for 2026.<\/p>\n